Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
- Momtazmanesh, Sara, Moghaddam, Sahar, Ghamari, Seyyed-Hadi, Rad, Elaheh, Rezaei, Negar, Shobeiri, Parnian, Aali, Amirali, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abdelmasseh, Michael, Abdoun, Meriem, Abdulah, Deldar, Md Abdullah, Abu, Abedi, Aidin, Abolhassani, Hassan, Abrehdari-Tafreshi, Zahra, Achappa, Basavaprabhu, Adane, Denberu, Adane, Tigist, Addo, Isaac, Adnan, Mohammad, Adnani, Qorinah, Ahmad, Sajjad, Ahmadi, Ali, Ahmadi, Keivan, Ahmed, Ali, Ahmed, Ayman, Rashid, Tarik, Al Hamad, Hanadi, Alahdab, Fares, Ur Rahman, Mohammad Hifz, oh, oi, oj, ok;, Rahman, Mosiur, Rahman, Muhammad Aziz
- Authors: Momtazmanesh, Sara , Moghaddam, Sahar , Ghamari, Seyyed-Hadi , Rad, Elaheh , Rezaei, Negar , Shobeiri, Parnian , Aali, Amirali , Abbasi-Kangevari, Mohsen , Abbasi-Kangevari, Zeinab , Abdelmasseh, Michael , Abdoun, Meriem , Abdulah, Deldar , Md Abdullah, Abu , Abedi, Aidin , Abolhassani, Hassan , Abrehdari-Tafreshi, Zahra , Achappa, Basavaprabhu , Adane, Denberu , Adane, Tigist , Addo, Isaac , Adnan, Mohammad , Adnani, Qorinah , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Keivan , Ahmed, Ali , Ahmed, Ayman , Rashid, Tarik , Al Hamad, Hanadi , Alahdab, Fares , Ur Rahman, Mohammad Hifz , oh, oi, oj, ok; , Rahman, Mosiur , Rahman, Muhammad Aziz
- Date: 2023
- Type: Text , Journal article
- Relation: eClinicalMedicine Vol. 59, no. (2023), p.
- Full Text:
- Reviewed:
- Description: Background: Updated data on chronic respiratory diseases (CRDs) are vital in their prevention, control, and treatment in the path to achieving the third UN Sustainable Development Goals (SDGs), a one-third reduction in premature mortality from non-communicable diseases by 2030. We provided global, regional, and national estimates of the burden of CRDs and their attributable risks from 1990 to 2019. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we estimated mortality, years lived with disability, years of life lost, disability-adjusted life years (DALYs), prevalence, and incidence of CRDs, i.e. chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease and pulmonary sarcoidosis, and other CRDs, from 1990 to 2019 by sex, age, region, and Socio-demographic Index (SDI) in 204 countries and territories. Deaths and DALYs from CRDs attributable to each risk factor were estimated according to relative risks, risk exposure, and the theoretical minimum risk exposure level input. Findings: In 2019, CRDs were the third leading cause of death responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) with a prevalence of 454.6 million cases (417.4–499.1) globally. While the total deaths and prevalence of CRDs have increased by 28.5% and 39.8%, the age-standardised rates have dropped by 41.7% and 16.9% from 1990 to 2019, respectively. COPD, with 212.3 million (200.4–225.1) prevalent cases, was the primary cause of deaths from CRDs, accounting for 3.3 million (2.9–3.6) deaths. With 262.4 million (224.1–309.5) prevalent cases, asthma had the highest prevalence among CRDs. The age-standardised rates of all burden measures of COPD, asthma, and pneumoconiosis have reduced globally from 1990 to 2019. Nevertheless, the age-standardised rates of incidence and prevalence of interstitial lung disease and pulmonary sarcoidosis have increased throughout this period. Low- and low-middle SDI countries had the highest age-standardised death and DALYs rates while the high SDI quintile had the highest prevalence rate of CRDs. The highest deaths and DALYs from CRDs were attributed to smoking globally, followed by air pollution and occupational risks. Non-optimal temperature and high body-mass index were additional risk factors for COPD and asthma, respectively. Interpretation: Albeit the age-standardised prevalence, death, and DALYs rates of CRDs have decreased, they still cause a substantial burden and deaths worldwide. The high death and DALYs rates in low and low-middle SDI countries highlights the urgent need for improved preventive, diagnostic, and therapeutic measures. Global strategies for tobacco control, enhancing air quality, reducing occupational hazards, and fostering clean cooking fuels are crucial steps in reducing the burden of CRDs, especially in low- and lower-middle income countries. Funding: Bill & Melinda Gates Foundation. © 2023 The Authors
- Authors: Momtazmanesh, Sara , Moghaddam, Sahar , Ghamari, Seyyed-Hadi , Rad, Elaheh , Rezaei, Negar , Shobeiri, Parnian , Aali, Amirali , Abbasi-Kangevari, Mohsen , Abbasi-Kangevari, Zeinab , Abdelmasseh, Michael , Abdoun, Meriem , Abdulah, Deldar , Md Abdullah, Abu , Abedi, Aidin , Abolhassani, Hassan , Abrehdari-Tafreshi, Zahra , Achappa, Basavaprabhu , Adane, Denberu , Adane, Tigist , Addo, Isaac , Adnan, Mohammad , Adnani, Qorinah , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Keivan , Ahmed, Ali , Ahmed, Ayman , Rashid, Tarik , Al Hamad, Hanadi , Alahdab, Fares , Ur Rahman, Mohammad Hifz , oh, oi, oj, ok; , Rahman, Mosiur , Rahman, Muhammad Aziz
- Date: 2023
- Type: Text , Journal article
- Relation: eClinicalMedicine Vol. 59, no. (2023), p.
- Full Text:
- Reviewed:
- Description: Background: Updated data on chronic respiratory diseases (CRDs) are vital in their prevention, control, and treatment in the path to achieving the third UN Sustainable Development Goals (SDGs), a one-third reduction in premature mortality from non-communicable diseases by 2030. We provided global, regional, and national estimates of the burden of CRDs and their attributable risks from 1990 to 2019. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we estimated mortality, years lived with disability, years of life lost, disability-adjusted life years (DALYs), prevalence, and incidence of CRDs, i.e. chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease and pulmonary sarcoidosis, and other CRDs, from 1990 to 2019 by sex, age, region, and Socio-demographic Index (SDI) in 204 countries and territories. Deaths and DALYs from CRDs attributable to each risk factor were estimated according to relative risks, risk exposure, and the theoretical minimum risk exposure level input. Findings: In 2019, CRDs were the third leading cause of death responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) with a prevalence of 454.6 million cases (417.4–499.1) globally. While the total deaths and prevalence of CRDs have increased by 28.5% and 39.8%, the age-standardised rates have dropped by 41.7% and 16.9% from 1990 to 2019, respectively. COPD, with 212.3 million (200.4–225.1) prevalent cases, was the primary cause of deaths from CRDs, accounting for 3.3 million (2.9–3.6) deaths. With 262.4 million (224.1–309.5) prevalent cases, asthma had the highest prevalence among CRDs. The age-standardised rates of all burden measures of COPD, asthma, and pneumoconiosis have reduced globally from 1990 to 2019. Nevertheless, the age-standardised rates of incidence and prevalence of interstitial lung disease and pulmonary sarcoidosis have increased throughout this period. Low- and low-middle SDI countries had the highest age-standardised death and DALYs rates while the high SDI quintile had the highest prevalence rate of CRDs. The highest deaths and DALYs from CRDs were attributed to smoking globally, followed by air pollution and occupational risks. Non-optimal temperature and high body-mass index were additional risk factors for COPD and asthma, respectively. Interpretation: Albeit the age-standardised prevalence, death, and DALYs rates of CRDs have decreased, they still cause a substantial burden and deaths worldwide. The high death and DALYs rates in low and low-middle SDI countries highlights the urgent need for improved preventive, diagnostic, and therapeutic measures. Global strategies for tobacco control, enhancing air quality, reducing occupational hazards, and fostering clean cooking fuels are crucial steps in reducing the burden of CRDs, especially in low- and lower-middle income countries. Funding: Bill & Melinda Gates Foundation. © 2023 The Authors
- Wunrow, Han, Bender, Rose, Vongpradith, Avina, Sirota, Sarah, Swetschinski, Lucien, Novotney, Amanda, Gray, Authia, Ikuta, Kevin, Sharara, Fablina, Wool, Eve, Aali, Amirali, Abd-Elsalam, Sherief, Abdollahi, Ashkan, Abdul Aziz, Jeza, Abidi, Hassan, Aboagye, Richard, Abolhassani, Hassan, Abu-Gharbieh, Eman, Adamu, Lawan, Adane, Tigist, Addo, Isaac, Adegboye, Oyelola, Adekiya, Tayo, Adnan, Mohammad, Adnani, Qorinah, Afzal, Saira, Aghamiri, Shahin, Aghdam, Zahra, Agodi, Antonella, Rahman, Muhammad Aziz
- Authors: Wunrow, Han , Bender, Rose , Vongpradith, Avina , Sirota, Sarah , Swetschinski, Lucien , Novotney, Amanda , Gray, Authia , Ikuta, Kevin , Sharara, Fablina , Wool, Eve , Aali, Amirali , Abd-Elsalam, Sherief , Abdollahi, Ashkan , Abdul Aziz, Jeza , Abidi, Hassan , Aboagye, Richard , Abolhassani, Hassan , Abu-Gharbieh, Eman , Adamu, Lawan , Adane, Tigist , Addo, Isaac , Adegboye, Oyelola , Adekiya, Tayo , Adnan, Mohammad , Adnani, Qorinah , Afzal, Saira , Aghamiri, Shahin , Aghdam, Zahra , Agodi, Antonella , Rahman, Muhammad Aziz
- Date: 2023
- Type: Text , Journal article
- Relation: The Lancet Neurology Vol. 22, no. 8 (2023), p. 685-711
- Full Text: false
- Reviewed:
- Description: Background: Although meningitis is largely preventable, it still causes hundreds of thousands of deaths globally each year. WHO set ambitious goals to reduce meningitis cases by 2030, and assessing trends in the global meningitis burden can help track progress and identify gaps in achieving these goals. Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we aimed to assess incident cases and deaths due to acute infectious meningitis by aetiology and age from 1990 to 2019, for 204 countries and territories. Methods: We modelled meningitis mortality using vital registration, verbal autopsy, sample-based vital registration, and mortality surveillance data. Meningitis morbidity was modelled with a Bayesian compartmental model, using data from the published literature identified by a systematic review, as well as surveillance data, inpatient hospital admissions, health insurance claims, and cause-specific meningitis mortality estimates. For aetiology estimation, data from multiple causes of death, vital registration, hospital discharge, microbial laboratory, and literature studies were analysed by use of a network analysis model to estimate the proportion of meningitis deaths and cases attributable to the following aetiologies: Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, group B Streptococcus, Escherichia coli, Klebsiella pneumoniae, Listeria monocytogenes, Staphylococcus aureus, viruses, and a residual other pathogen category. Findings: In 2019, there were an estimated 236 000 deaths (95% uncertainty interval [UI] 204 000–277 000) and 2·51 million (2·11–2·99) incident cases due to meningitis globally. The burden was greatest in children younger than 5 years, with 112 000 deaths (87 400–145 000) and 1·28 million incident cases (0·947–1·71) in 2019. Age-standardised mortality rates decreased from 7·5 (6·6–8·4) per 100 000 population in 1990 to 3·3 (2·8–3·9) per 100 000 population in 2019. The highest proportion of total all-age meningitis deaths in 2019 was attributable to S pneumoniae (18·1% [17·1–19·2]), followed by N meningitidis (13·6% [12·7–14·4]) and K pneumoniae (12·2% [10·2–14·3]). Between 1990 and 2019, H influenzae showed the largest reduction in the number of deaths among children younger than 5 years (76·5% [69·5–81·8]), followed by N meningitidis (72·3% [64·4–78·5]) and viruses (58·2% [47·1–67·3]). Interpretation: Substantial progress has been made in reducing meningitis mortality over the past three decades. However, more meningitis-related deaths might be prevented by quickly scaling up immunisation and expanding access to health services. Further reduction in the global meningitis burden should be possible through low-cost multivalent vaccines, increased access to accurate and rapid diagnostic assays, enhanced surveillance, and early treatment. Funding: Bill & Melinda Gates Foundation. © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. **Please note that there are multiple authors for this article therefore only the name of the first 30 including Federation University Australia affiliate “Muhammad Aziz Rahman” is provided in this record**
- «
- ‹
- 1
- ›
- »